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Radiation and Chemical Injury in the
Bone Marrow
by Anatoly Dritschilo,* and David S. Shermant
Hematopoietic system toxicity is a major limiting factor in the use of aggressive combined
modality therapy in the treatment of malignant disease. In this review, the known drug-x-ray
interactions using tissue culture systems are extended to the bone marrow compartment. Two
hypotheses prevail for late bone marrow failure: (1) stromal damage to the vasculature with
subsequent fibrosis and (2) irreversible stem cell depletion in the irradiated site.
Clinical extensions of the experimental data for bone marrow kinetics in the animal model
have not proven successful to date. The future strategies for therapy of malignancies in which
both radiation and chemotherapy are employed may require dose modification or treatment
planning to limit bone marrow toxicity.
Introduction
Current approaches to the successful manage-
ment of malignancies include combined modality
treatment. The ability of radiation therapy to
control localized disease and of chemotherapy to
control micrometastases suggests a complimentary
nature for the two modalities. Using this principle
and the possibility of potentiation of therapeutic
effects, combined modality efforts have been tested
in a variety ofclinical situations. Diseases in which
this approach has been most successful include
pediatric, hematological, breast, and gastrointesti-
nal malignancies (1).
Enthusiasm over early results; however, must be
tempered by an increased acute toxicity and the
potential late effects of combined therapy. Hema-
topoietic system toxicity is a major limiting factor
when aggressive combined therapy is employed.
Clinically significant bone marrow injury may re-
sultin acute changes such asdepletion ordepopulation
of stem cells and resultant organ failure, or late
effects contributing to malignant transformation.
Drug injury to the bone marrow has been additive
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to radiation injury. By combining radiation therapy
and chemotherapy, increased toxicity rather than
an improvement in the therapeutic ratio may be
observed (2).
In this review we intend to consider the known
radiation-tissue interactions, the influences ofdrugs
on these interactions, characterization ofbone mar-
row injury, and laboratory-clinical correlations.
Animal data for bone marrow investigations provid-
ing insight into these interactions will be reviewed
and compared to interactions in other mammalian
tissue culture systems. The feasibility ofusing this
current knowledge in developingtherapeutic strate-
gies for drug x-ray sequencing will be discussed.
Physics and Radiobiological
Considerations
The basic radiation-matter interaction for ioniz-
ing radiation in the therapeutic energy range con-
sists of Compton scattering of an x-ray photon and
an orbital electron (Fig. 1). Subsequent interac-
tions result in deposition ofenergy by the scattered
electron in critical "target sites" in the cell. These
are generally believed to be interactions with
DNA. At the cellular level there remain many gaps
in the knowledge ofmechanism ofradiation injury.
Theoretical models based on microdosimetric con-
siderations and on DNA breakage results in a
59double exponential equation describing the radia-
tion response of cells (3, 4). From a practical
viewpoint, however, most data is analyzed using
classical target theory (5).
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FIGURE 1. Radiation-matterinteraction illustrating anincident
photon (x-ray) interacting with a loosely bound electron
giving rise to the Compton electron.
The cell cloning and colony forming techniques
originally described by Puck and Marcus in 1956
have led to semilogarithmic dose response curve for
mammalian cells and to a concept of log kill with
radiation (6). The concept is based on cells losing or
maintaining the capacity for unlimited division to
form colonies. Using a different technique and
chemotherapeutic agents, Skipper et al. developed
the concept offractional kill in 1964 (7). In practice,
the two approaches represent a single concept with
implications for cure of disease and tolerance to
treatment.
Since the mechanism of radiation injury and
repair are not well established, much ofthe charac-
terizations of radiation-cell interactions are based
on functional definitions of radiation damage and
repair using the colony forming assay systems. In
particular, mammalian cells have been shown to
demonstrate two operationally different repair
processes.
Sublethal damage (SLD) repair is expressed as
the increase in survival observed as the interval
between two doses is increased (8). Potentially
lethal damage (PLD) repair is expressed by the
increase in survival following a single dose when
post-irradiation conditions are appropriate (9). Fig-
ure 2 illustrates a proposed hierarchy of radiation
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FIGURE 2. Interrelationship of levels of radiation injury.
SLD-sublethal radiation damage, PLD-potentially lethal ra-
diation damage.
damage. A cell may skip an intermediate damage
level when injury or repair processes occur (10).
The actions of chemotherapeutic agents on cells
may result in exponential or biphasic killing curves
(11). Actions of drugs and radiation on cells may
result in these categories: (1) additivity, i.e., inde-
pendent actions ofdrug and radiation are combined;
(2) potentiation, i.e., nontoxic doses of a drug
combined with radiation results in enhancement of
radiation damage; and (3) synergism, i.e., the
combined effect is greater than the simple addition
ofactions ofthe individual modalities. The radiation
survival curve may be changed (decrease the capacity
ofcells to accumulate SLD) or the ability ofcells to
repair SLD or PLD may be impaired (12, 13). Table
1 summarizes known drug-radiation interactions
for several frequently used chemotherapeutic agents.
A "recall" phenomenon is observed when there is
an enhanced reaction in an irradiated volume on
treatment with drugs weeks following completion
of irradiation.
Although radiation cell killing occurs in all phases
ofthe mitotic cycle, cells exhibit varying degrees of
sensitivity throughout the cycle. Figure 3 illus-
trates that cells are most sensitive in G2M phase
and least sensitive in late S phase (14). Cell
cycle-specific drugs may be more effective (or more
toxic) ifappropriate drug-x-ray sequencing is used.
Table 1. Drug-radiation interactions.
X-ray interaction
Poten- Repair
Drug tiate inhibition "Recall"
Alkylating agents
Cyclophosphamide +
Melphalan
Antimetabolite
5FU +
Methotrexate 4- +
Antitumor antibiotics
Adriamycin + + +
Bleomycin + + +
Actinomycin D + + +
Miscellaneous
Vincristine +
BCNU +
Cis-Platinum + +
Hydroxyurea +
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FIGURE 3. Relative radiation sensitivities of mammalian cells
in the stages of the mitotic cycle (14).
Radiation Effects on Bone Marrow
Much has been written on the effects of irradia-
tion on hematopoietic tissues. The assay on which
much ofthe experimental data is based is the spleen
colony method of Till and McCulloch (15, 16).
Usually donor mice undergo variable radiation or
drug treament and recipients undergo lethal irradi-
ation. Bone marrow is transplanted and maroscopic
spleen colonies are counted 8-10 days later. Figure
4 illustrates data ofTill and McCulloch showing the
radiation survival curve for mouse bone marrow
stem cells (CFU-s).
The ability of the bone marrow compartment to
recover and regenerate following irradiation is
principally dependent on two factors, the dose of
radiation and the volume ofbone marrow within the
irradiated field (17-19). The acute depletion ofbone
marrow components following irradiation have been
ascribed to the direct effect of radiation depleting
the stem cell compartment, whereas the chronic
bone marrow aplasia following initial repopulation
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FIGURE 4. Radiation dose response curve for mouse bone
marrow cells using the spleen colony assay system. From Till
and McCullough (15, 16).
has been ascribed to stromal damage thought
secondary to an impaired vascular supply and
subsequent fibrosis. This has been attributed to
endothelial cell damage. The delay in the expres-
sion ofdamage beingthe result ofthe prolonged cell
division in the stroma.
An alternate hypothesis of late marrow failure
has been an irreversible stem cell depletion within
the irradiated site. The prime argument against
such an hypothesis has been the observation that
migrating stem cells are capable of repopulating
irradiated bone marrow as demonstrated with whole
body irradiation when portions ofbone marrow are
shielded (20, 21). Questions have been raised to the
efficacy ofthis migrating stem cell pool, both in the
total numbers ofcirculating CFU's available, and in
their ability to maintain the capacity for unlimited
self renewal as would be required of a true stem
cell. Hellman et al. have shown in C3H/HEJ mice
that the circulating stem cell pool is very small,
perhaps as few as 100, and is rapidly exhausted
following radiation (22). Micklem et al. have shown
that circulating stem cells show low proliferative
potential and cease to multiply after a certain
number ofdivisions (23). Additionally, little migra-
tion of stem cells normally occurs between the
marrow of different bones (24, 25). Functional
studies ofthe ability ofthe bone marrow to support
clonigenic proliferation have shown a dose related
61decrease at all times following radiation (26). Acute
recovery following radiation and subsequent late
marrow failure does not disprove the stem cell
depletion concept.
Despite initial acute recovery inthe bone marrow
following single doses of radiation as high as 6000
rad, the bone marrow is seen to become aplastic at
late times post radiation. The degree and time
interval to aplasia is dependent on the dose of
radiation (27).
Conventionally, fractionated doses ofradiation of
greaterthan 3000 to 4000 rad as observed by Sykes
FIGURE 5. Distribution of bone marrow in the adult (35, 36).
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have been shown to cause permanent aplastic
changes in the bone marrow in over 90% of such
treated patients (28, 29).
Attemptshavebeenmadetoartificiallyrepopulate
irradiated bone marrow sites with presumably
viable stem cells by means of intravenous bone
marrow infusion (30). Animal studies have gener-
allybeen unsuccessful in showing any lastingbenefit
to irradiate sites using this technique. Knospe gave
bone marrow infusion 10 days or3 months following
irradiation without evidence of benefit, although
quantative measurements of cellularity or CFU
were not attempted in these experiments.
Recent data by Buachidze using autologous bone
marrow transplantation in patients receiving total
nodal irradiation for Hodgkin's disease have been
presented (31). An initial acute benefit was shown
for patients who received bone marrow transplan-
tation in both platelet and granulocyte counts
during and shortly following irradiation. No infor-
mation has yet been persented as to the longetivity
of these acute early responses to marrow trans-
plantation. Acute depletion of the bone marrow
failure at sufficient doses would appear to be due
both to stromal damage secondary to impairment of
the vascular supply as well as to the direct effect of
radiation on depletion of the stem cell compart-
ment. This localized stem cell depletion and stromal
damage cannot at this time be replenished either
with endogenous circulating stem cells or the exog-
enous infusion of donor stem cells within the
irradiated sites.
Clinical Evaluation of Bone
Marrow Toxicity
Although drugs effect the entire bone marrow
volume, radiation effects are primarily confined to
treated volumes. The fraction ofbone marrow that
will undergo irradiation may be estimated for a
planned treatment course. Figure 5 presents the
Table 2. Proportion of bone marrow irradiated by usual
therapeutic techniques.
Estimated bone marrow
Radiation technique affected, %
Total body irradiation 100
Total nodal irradiation 60-70
Mantle 20-50
Para-aortic 20-25
Pelvic 15-25
Pulmonary and mediastinal 20-25
Abdominal 20-25
Cranial 25-45
Cranio-spinal 60-75
Chest wall and lymphatic 15-20
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No. of
Reference patients Evaluation method Dose (rad) Observations
Sykes et al. (28) 61 Sternal marrow histology 1000-2400 Complete recovery 5/5
3000-6000 Partial recovery 2/56
Slanina et al. (33) 73 Sternal marrow histology 3000-5000 Normal 4%
Hypoplastic 16%
Aplasia 80%
89 Iliac crest marrow histology Unirradiated Normal 53%
Hypoplasia 47%
Aplasia 0
Rubin et al. (19) 27 99mTc-S Scan 4000 Recovery at 1 year 50%
Recovery at 2-3 years 80%
Knospe et al. (34) 26 52Fe Scan 4000-4400 Marrow volume expression
0-12 months 8/10
12-24 months 7/8
>24 months 1/8
data ofHashimoto and Atkinson illustrating that in
the adult, truncal bones and proximal extremities
contain the majority ofthe active bone marrow (35,
36). The fractional volumes of bone marrow in-
cluded in the usual portal for various sites of
irradiation are presented in Table 2. As may be
observed, significant marrow fractions are in the
radiation fields for most diseases in which radiation
and chemotherapy play a role and may relate to
subsequent toxicity and poor tolerance when drugs
are required. To some degree, more careful treat-
ment planning, to minimize bone marrow irradiated,
may improve this situation.
The use of animal data may certainly provide
insight into basic principles; however, most animal
studies are performed with large single dose expo-
sures and are of limited value in predicting human
bone marrow regeneration. Table 3 summarizes
four reports of clinical evaluations of bone marrow
following radiation therapy.
Although these studies were performed by eval-
uating bone marrow histology, or radioisotope
uptake, they do provide abasis for several clinically
important conclusions: (1) there is a high incidence
ofaplasia at doses above 3000 rad; (2) results in the
peripheral blood may not directly correspond to
bone marrow observations (33); and (3) the kinetics
of regeneration of bone marrow in humans are not
established, and may be important for combined
modality treatment considerations.
Future Prospects
Experimental results in the animal system do not
directly correlate to clinical observations; however,
mechanisms and generalizations may be formulat-
ed. The goal will be to apply these concepts to
attain optimal timing, sequencing, and dosages of
radiation and drugs. Attempts to use infusion of
autologous bone marrow have not provided any
major benefits at this time. As our knowledge and
technical capabilities forbone marrow transplantation
increase, this may become a reasonable option. In
the immediate future, optimal sequencing of drugs
and irradiation, along with dose modification ap-
pears to be the most feasible approach to limiting
bone marrow toxicity.
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